Xtandi 40mg is nonsteroidal antiandrogen formulation which is prescribed for treatment of prostate cancer. It is formulated having enzalutamide as main chemical ingredient having molecular formula C21H16F4N4O2S with molar mass of 464.44 g/mol. This medicine is selective antagonist to androgen receptor and prevents effects of testosterone & dihydrotestosterone in prostate gland. It has about 84.6% of bioavailability with protein binding ability of 97 to 98%. Metabolism of Xtandi 40mg takes place in liver with help of CYP2C8 & CYP3A4 and shows average elimination half life of 5.8 days.